Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9902657 | 0.95 | ALDH1A1 (0.52) | ALDH1A1POLBEPHX2 | |
| SCHEMBL9902487 | 0.88 | ALDH1A1 (0.47) | ALDH1A1POLBEPHX2 | |
| SCHEMBL9902315 | 0.85 | EPHX1 (0.49) | ALDH1A1POLBEPHX2 | |
| SCHEMBL9902595 | 0.84 | SMN1; SMN2 (0.47) | ALDH1A1EPHX2 | |
| SCHEMBL14045968 | 0.79 | EPHX2 (0.48) | ALDH1A1POLBEPHX2 | |
| SCHEMBL9903173 | 0.79 | EPHX1 (0.47) | ALDH1A1EPHX2 | |
| SCHEMBL9901315 | 0.79 | ALDH1A1 (0.50) | ALDH1A1POLBEPHX2 | |
| SCHEMBL9901463 | 0.77 | ALDH1A1 (0.53) | ALDH1A1EPHX2 | |
| SCHEMBL17271394 | 0.76 | ALDH1A1 (0.32) | ALDH1A1EPHX2 | |
| SCHEMBL10756515 | 0.75 | POLB (0.70) | ALDH1A1POLBEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107198-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | TISBURY PHARMACEUTICALS, INC | 2017-04-20 | — | — | US | disclosed |
| US-9522903-B2 | Multifunctional nitroxide derivatives and uses thereof | RADIKAL THERAPEUTICS INC. (US) | 2016-12-20 | — | — | US | disclosed |
| EP-2649048-B1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | RADIKAL THERAPEUTICS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20150336932-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | TISBURY PHARMACEUTICALS, INC | 2015-11-26 | — | — | US | disclosed |
| US-9102659-B2 | Multifunctional nitroxide derivatives and uses thereof | RADIKAL THERAPEUTICS INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20130338146-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | RADIKAL THERAPEUTICS INC. (US) | 2013-12-19 | — | — | US | disclosed |
| EP-2649048-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | Radikal Therapeutics Inc. (US) | 2013-10-16 | — | — | EP | disclosed |
| CN-103347856-A | Multifunctional nitroxide derivatives and uses thereof | RADIKAL THERAPEUTICS INC | 2013-10-09 | — | — | CN | disclosed |
| WO-2012077108-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | RADIKAL THERAPEUTICS INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130338146-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | NOX4, NOX1, NOX3 | ALDH1A1 1804/4885POLB 2898/4885EPHX2 2467/4885 |
| US-20170107198-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | NOX4, NOX1, NOS1 | ALDH1A1 1794/4885POLB 2803/4885EPHX2 2392/4885 |
| US-20150336932-A1 | MULTIFUNCTIONAL NITROXIDE DERIVATIVES AND USES THEREOF | NOX4, NOX1, NOX3 | ALDH1A1 1804/4885POLB 2898/4885EPHX2 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.